The aim of our work was to develop a fast, reliable and sensitive PCR method to detect K-ras mutations in various clinical samples. There is a need for an unimpeachable method for early diagnosis and/or screening of pancreatic cancer (PC). We optimized and subsequently analyzed four methods based on mutant-enriched PCR for the sensitivity, cost and time expense. Using the selected optimal method we examined codon 12 K- ras mutations in a study population of 59 patients with upper GIT malignancies. Reliability of the genotyping was confirmed by sequencing. By using the best of our modified mutant-enriched PCR methods we achieved sensitivity of 1:1 x 10(5). Further studies are necessary to determine the optimal biological material sampling in PC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer.
Oncol Lett
December 2023
Department of Pathology, National Cheng Kung University Hospital, Tainan 704, Taiwan, R.O.C.
Article Synopsis
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are commonly used to treat non-small cell lung cancer (NSCLC) in patients with confirmed EGFR mutations, but false negatives in molecular tests can occur.
- A pilot study using peptide nucleic acid (PNA) clamping-sequencing, which is highly sensitive, showed promising results in better identifying patients who would benefit from EGFR-TKI therapy.
- Data from 1,783 lung cancer cases indicated that combining RT-qPCR with PNA-sequencing improves the accuracy of detecting EGFR mutations, potentially leading to better treatment decisions and longer patient survival.
Quantification of Isoniazid-Heteroresistant Mycobacterium tuberculosis Using Droplet Digital PCR.
J Clin Microbiol
June 2023
Engineering Research Centre of Molecular Diagnostics of Ministry of Education, State Key Laboratory of Cellular Stress Biology, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, China.
The quantitative detection of drug-resistance mutations in Mycobacterium tuberculosis (MTB) is critical for determining the drug resistance status of a sample. We developed a drop-off droplet digital PCR (ddPCR) assay targeting all major isoniazid (INH)-resistant mutations. The ddPCR assay consisted of three reactions: reaction A detects mutations at S315; reaction B detects promoter mutations; and reaction C detects promoter mutations.
View Article and Find Full Text PDFDetection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen® FFPE BRAF qPCR assay.
PLoS One
February 2023
Institute of Pathology EOC, Ente Ospedaliero Cantonale, Locarno, Switzerland.
Mutations in BRAF exon 15 lead to conformational changes in its activation loops, resulting in constitutively active BRAF proteins which are implicated in the development of several human cancer types. Different BRAF inhibitors have been developed and introduced in clinical practice. Identification of BRAF mutations influences the clinical evaluation, treatment, progression and for that reason a sensitive and specific identification of BRAF mutations is on request from the clinic.
View Article and Find Full Text PDFAsymmetric mutant-enriched polymerase chain reaction and quantitative DNA melting analysis of KRAS mutation in colorectal cancer.
Anal Biochem
February 2020
Institute of Carcinogenesis, N.N. Blokhin Cancer Research Center, Kashirskoe Shosse 24, 115478, Moscow, Russia. Electronic address:
Identification of mutant genes in tumor tissues and blood plasma (solid and liquid biopsy samples, respectively) is a necessity for individualized treatment of cancer patients. Here we report the use of a novel mutant-enriched PCR - quantitative DNA melting curve analysis (mePCR-qDMA) with TaqMan probes. The TaqMan probes served as blocking agents during PCR and as hybridization probes during DNA melting curve analyses.
View Article and Find Full Text PDFIntratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
J Cancer Res Clin Oncol
January 2019
Department of Clinical Physiology, Medical University of Lodz, Mazowiecka St. 6/8, 92-215, Lodz, Poland.
Purpose: Mutated KRAS oncogene in exhaled breath condensate (EBC) can be a genetic marker of non-small cell lung cancer (NSCLC). However, a possibility of inhomogeneous distribution in cancer tissue and intratumor heterogeneity of KRAS mutation may decrease its significance. We investigated a status of KRAS point mutation and its sequence at codon 12 in 51 NSCLC patients after tumor resection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!